TITLE:
Benefit of Targeted Therapies in Metastatic Colon Cancer in the Ivorian Context
AUTHORS:
Touré Moctar, Kouassi Kouamé K. Yvon, Séka E. Narcisse, Traoré Kady, Kimso Oumou, Niang D. Rokhaya, Odo B. Adde, Oseni Jelili, Adoubi Innocent
KEYWORDS:
Cancer-Colon-Metastasis-Targeted Therapy
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.8 No.8,
August
15,
2017
ABSTRACT: In our daily practice, the use of targeted therapies
(Bevacizumab and rarely Cetuximab) in metastatic colic cancers is recent. Very
few patients benefit from these therapies because of their high cost. In a
cohort of 68 patients who received these therapies, a retrospective and
prospective study was conducted over three years period (1 January 2013 to 31
December 2015) to evaluate their benefit in terms of quality of life, tolerance
and overall survival. These targeted therapies provided a significant clinical
and biological gain with acceptable toxicities (most often resolving
spontaneously). Moreover, they have allowed a significant improvement in
overall survival in first line metastatic treatment. The limiting factor
remains their extremely high cost and therefore inaccessibility to the majority
of our patients.